
CLAIMS:

1. A compound of Formula (I)



(I),

or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof,

wherein

X is N;


p is 1 or 2;

v is 1 or 2;

m is 1, 2, or 3;

n is 0;

t is 1 or 2;

Ring A is  , wherein **2 refers to the position attached to phenyl;

Ring B is phenyl, furanyl, isoxazolyl, pyridinyl, pyrazolyl, or pyrimidinyl;

L^2 is a-$(CH_2)_q$- or -O-, wherein q is a number of 1 to 3;

R^{11} is

(i) chromanyl, benzo[b][1,4]dioxinyl,5,6,7,8-tetrahydronaphthalenyl, octahydro-5H-2,5-methanoindenyl, 2,3,4,5-tetrahydrobenzo[b]oxepinyl, adamantanyl, each of which is optionally substituted with 1 or 2 R^{11X};

(ii) furan-2-yl, isoxazol-4-yl, pyridin-3-yl, pyridin-2-yl, 1H-pyrazol-4-yl, pyrimidin-2-yl, benzo[b]thiophen-5-yl, benzo[b]thiophen-4-yl, benzofuran-5-yl, or benzofuran-4-yl; or

(iii) phenyl substituted with cyano, fluoro, chloro, bromo, methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, methoxy, ethoxy, propoxy, isopropoxy, butoxy, tert-butoxy, difluoromethyl,

trifluoromethyl, trifluoromethoxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, oxetan-3-yl, cyclopropoxy, cyclobutoxy, cyclopentoxy, cyclohexoxy, $-NH_2$, or $-NH(CH_3)$;

R^{11X}, at each occurrence, is independently halogen, $-C_{1-8}$alkyl, haloC_{1-8}alkyl, $-C_{2-8}$alkenyl, $-C_{2-8}$alkynyl, $-C_{3-8}$cycloalkyl, heterocyclyl, aryl, heteroaryl, oxo, -CN, $-NO_2$, $-OR^{11a}$, $-SO_2R^{11a}$, $-COR^{11a}$, $-CO_2R^{11a}$, $-CONR^{11a}R^{11b}$, $-C(=NR^{11a})NR^{11b}R^{11c}$, $-NR^{11a}R^{11b}$, $-NR^{11a}COR^{11b}$, $-NR^{11a}CONR^{11b}R^{11c}$, $-NR^{11a}CO_2R^{11b}$, $-NR^{11a}SONR^{11b}R^{11c}$, $-NR^{11a}SO_2NR^{11b}R^{11c}$, $-P(=O)R^{11a}R^{11b}$, or $-NR^{11a}SO_2R^{11b}$, wherein said C_{3-8}cycloalkyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with halogen, $-C_{1-8}$alkyl, -haloC_{1-8}alkyl, $-C_{1-8}$alkoxyl, or -haloC_{1-8}alkoxyl;

R^{11a}, R^{11b}, and R^{11c} are each independently hydrogen, $-C_{1-8}$alkyl, -haloC_{1-8}alkyl, $-C_{2-8}$alkenyl, $-C_{2-8}$alkynyl, $-C_{3-8}$cycloalkyl, heterocyclyl, aryl, or heteroaryl, wherein said C_{3-8}cycloalkyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with halogen, $-C_{1-8}$alkyl, -haloC_{1-8}alkyl, $-C_{1-8}$alkoxyl, or -haloC_{1-8}alkoxyl;

each R^2 is independently halogen, $-C_{1-8}$alkyl, $-C_{2-8}$alkenyl, $-C_{2-8}$alkynyl or $-C_{3-6}$cycloalkyl; wherein said $-C_{1-8}$alkyl, $-C_{2-8}$alkenyl, $-C_{2-8}$alkynyl or $-C_{3-6}$cycloalkyl is each independently optionally substituted with halogen, hydroxy, C_{1-6}alkoxy, amino, $-C_{1-8}$alkyl, $-C_{2-8}$alkenyl, $-C_{2-8}$alkynyl, C_{3-6}cycloalkyl or C_{3-6}heterocyclyl;

R^3 is $-L^1$-CyC,

wherein

L^1 is a direct bond, $-(CR^aR^b)_{1-4}$-, -O-$(CR^aR^b)_{0-3}$-, -NH-$(CR^aR^b)_{1-3}$, -NHC(O)NR^a-$(CR^aR^b)_{1-3}$, or -NH-;

CyC is cycloalkyl, or heterocyclyl, each of which is optionally substituted with one, two, three or four substituents R^{3a};

each R^{3a} is independently halogen, cyano, oxo, $-OR^{3b}$, $-NR^{3b}R^{3c}$, $-COR^{3b}$, $-SO_2R^{3b}$, $-C_{1-8}$alkyl, $-C_{2-8}$alkenyl, $-C_{2-8}$alkynyl, -cycloalkyl, or heterocyclyl, wherein each of said $-C_{1-8}$alkyl, and heterocyclyl is optionally substituted with one, or two substituents R^{3e} which is selected from halogen, cyano, $-OR^{3f}$, $-C_{1-8}$alkyl, -cycloalkyl, or heterocyclyl;

R^{3b}, and R^{3c} are each independently hydrogen, $-C_{1-8}$alkyl, -cycloalkyl, or heterocyclyl, wherein said $-C_{1-8}$alkyl is optionally substituted with one or two substituents R^{5e} which is $NR^{3f}R^{3g}$, -cycloalkyl, or heterocyclyl;

R^{3f} and R^{3g} are each independently hydrogen or $-C_{1-8}$alkyl;

or, two adjacent R^3 on the phenyl ring together with the phenyl ring form a benzo ring, wherein said ring is optionally substituted with heteroaryl;

R^a and R^b are each independently hydrogen, $-C_{1-8}$alkyl, $-C_{2-8}$alkenyl, $-C_{2-8}$alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl; and,

R^4 and R^5 are each independently hydrogen, halogen, cyano, $-NO_2$, $-C_{1-8}$alkyl, $-C_{2-8}$alkenyl, or $-C_{2-8}$alkynyl.


2. The compound of claim 1, wherein each R^2 is independently halo, $-C_{1-6}$alkyl or $-C_{3-4}$cycloalkyl; wherein said $-C_{1-6}$alkyl and $-C_{3-4}$cycloalkyl are each independently optionally substituted with $-C_{1-3}$alkyl, C_{3-6}cycloalkyl or C_{3-6}heterocyclyl; and q is a number of 1.

3. The compound of claim 1, wherein R^2 is fluoro, methyl, isopropyl, isobutyl, cyclopropyl, cyclobutyl or morpholinomethyl.

4. The compound of claim 1, wherein R^{11X} is halogen, cyano, hydroxy, -C_{1-8}alkyl, haloC_{1-8}alkyl, -C_{2-8}alkenyl, -C_{2-8}alkynyl, C_{1-6}alkoxyl, haloC_{1-6}alkoxyl, C_{3-6}cycloalkyl, heterocyclyl, C_{3-6}cycloalkoxyl, -NH_2, -$NH(C_{1-8}alkyl)$, -$N(C_{1-8}alkyl)_2$ or heterocyclyl-O-.

5. The compound of claim 1, wherein m is 1, R^3 is –L^1-CyC, and L^1 is a direct bond, -$(CH_2)_{1-2}$-, -$NH(CH_2)_{0-2}$-, or -$O(CH_2)_{0-2}$-.

6. The compound of claim 1, wherein CyC is

a) cycloalkyl selected from monocyclic C_{3-8}cycloalkyl or bridged cycloalkyl (), each of which is optionally substituted with one or two substituents R^{3a}; or

b) heterocyclyl selected from monocyclic 4 to 9-membered heterocyclyl groups containing one nitrogen or oxygen or sulfur heteroatom as ring member; monocyclic 4 to 9-membered heterocyclyl groups containing two heteroatoms selected from oxygen, sulfur, and nitrogen as ring members, which is optionally substituted with one, two, three or four substituents R^{3a}; or

c) 5- to 10-membered spiro heterocyclyl comprising one or two heteroatoms selected from nitrogen, sulfur, and oxygen as ring members, which is optionally substituted with one, two, three or four substituents R^{3a}; or

d) 5- to 10-membered bridged heterocyclyl comprising one or two heteroatoms selected from nitrogen, sulfur, and oxygen as ring members, which is optionally substituted with one, two, three or four substituents R^{3a}; or

e) a monocyclic 6-membered heterocyclyl group containing two heteroatoms selected from oxygen and nitrogen as ring members; or

f) 4-membered/4-membered, 3-membered/5-membered, 4-membered/5-membered, 4-membered/6-membered, 5-membered/5-membered, or 5-membered/6-membered mono-spiro heterocyclyl comprising one or two nitrogen or oxygen as ring members.

7. The compound of claim 6, wherein CyC is

(i) cyclobutyl, cyclopentyl or cyclohexyl, each of which is optionally substituted with one or two substituents R^{3a}; or



(ii) a monocyclic 4 to 6-membered heterocyclyl groups containing one nitrogen or oxygen or sulfur heteroatom as the ring members; or

(iii) oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, azetidinyl, pyrrolidinyl, and piperidinyl;

(iv) dioxanyl, morpholino, morpholinyl, or piperazinyl; or

(v) 1,3-dioxan-2-yl, 1,3-dioxan-4-yl, 1,4-dioxan-2-yl, morpholin-1-yl, morpholin-2-yl, or morpholin-3-yl.

8. The compound of claim 7, wherein CyC is selected from oxetan-2-yl, Oxetan-3-yl, tetrahydrofuran-4-yl, tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, tetrahydropyran-2-yl, tetrahydropyran-3-yl, tetrahydropyran-4-yl, azetidin-3-yl, azetidin-2-yl, pyrrolidin-2-yl, pyrrolidin-3-yl, piperidin-4-yl, piperidin-2-yl, and piperidin-3-yl.

9. The compound of claim 6, wherein CyC is  (7-oxa-2-azaspiro[3.5]nonan-2-yl), or  (2-oxaspiro[3.5]nonan-7-yl).

10. The compound of claim 9, wherein each R^{3a} is independently halogen, cyano, oxo, $-OR^{3b}$, $-NR^{3b}R^{3c}$, $-C(=O)R^{3b}$, $-SO_2R^{3b}$, $-C_{1-6}$alkyl, monocyclic C_{3-6}cycloalkyl, or monocyclic 4 to 9-membered heterocyclyl group containing one or two heteroatoms selected from nitrogen or oxygen or sulfur heteroatom as ring members, each of said $-C_{1-6}$alkyl and monocyclic 4 to 9-membered heterocyclyl group is optionally substituted with one or two substituents R^{3e}.

11. The compound of claim 10, wherein

a) R^{3a} is C_{3-6}cycloalkyl; or

b) R^{3a} is 4 to 6-membered heterocyclyl groups containing one or two heteroatoms selected from nitrogen or oxygen or sulfur heteroatom as ring members; or

c) R^{3a} is oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, piperazinyl, or morpholinyl; or

d) R^{3a} is oxetan-3-yl, tetrahydrofuran-3-yl, tetrahydro-2H-pyran-4-yl, or morpholin-4-yl; or

e) R^{3e} is monocyclic 4 to 9-membered heterocyclyl group containing one or two heteroatoms selected from nitrogen or oxygen or sulfur heteroatom as ring members; or

f) R^{3e} is tetrahydro-pyran-4-yl; or

g) R^{3a} is $-NR^{3b}R^{3c}$, wherein R^{3b} is hydrogen, and R^{3c} is heterocyclyl; or


h) R^{3a} is $-NR^{3b}R^{3c}$, wherein R^{3b} is hydrogen, and R^{3c} is tetrahydro-pyran-4-yl; or


i) R^{3a} is $-NR^{3b}R^{3c}$, wherein R^{3b} and R^{3c} are each independently hydrogen or $-C_{1-6}$alkyl substituted with cycloalkyl; or

j) R^{3a} is $-OR^{3b}$ or $-SO_2R^{3b}$, wherein R^{3b} is hydrogen or C_{1-8}alkyl; or

k) R^{3a} is $-COR^{3b}$, wherein R^{3b} is hydrogen or C_{1-6}alkyl optionally substituted with $-NR^{3f}R^{3g}$, wherein R^{3f} and R^{3g} are each independently hydrogen or C_{1-6}alkyl.


12. The compound of claim 1, wherein m is 1 and R^3 is selected from the group consisting of:






13. A compound or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the


group consisting of:




(Ex. 19);




or




(Ex. 19a);




or




(Ex. 19b);




(Ex. 20);




(Ex. 21);




(Ex. 22);




or




(Ex. 22a) and (Ex. 22b);




(Ex. 23);




(Ex. 24a) and (Ex. 24b);




(Ex. 25a) and (Ex. 25b);




(Ex. 26);




(Ex. 27);




(Ex. 28);




or




(Ex. 28a);




(Ex. 29);




or




(Ex. 29a);




(Ex. 30);




(Ex. 31);




or




(Ex. 32);




or




(Ex. 33);




(Ex. 34);




(Ex. 35);




(Ex. 36);




(Ex. 37);




(Ex. 38);




(Ex. 39);




(Ex. 40);




(Ex. 41);




(Ex. 42);




(Ex. 43);




(Ex. 44);




(Ex. 45);




(Ex. 46);




(Ex. 47);




(Ex. 48);




or




(Ex. 48a);




(Ex. 49);




(Ex. 50);




(Ex. 51);




(Ex. 52);




or




(Ex. 52a);




(Ex. 53);




(Ex. 54);




(Ex. 55);




(Ex. 56);




(Ex. 57);




(Ex. 58);




(Ex. 59);




(Ex. 60);




(Ex. 61);




(Ex. 62);




(Ex. 63);




(Ex. 64a) and (Ex. 64b);




(Ex. 65);




(Ex. 67);




(Ex. 68);




or




(Ex. 69);




(Ex. 70);




(Ex. 71);




(Ex. 72);




(Ex. 73);




(Ex. 74);




(Ex. 75);




(Ex. 76);




(Ex. 77);




(Ex. 78);




(Ex. 79);




(Ex. 79a);




(Ex. 79b);




(Ex. 80a) and (Ex. 80b);




(Ex. 81);




(Ex. 81a);




(Ex. 81b);




(Ex. 82);




(Ex. 83);




or




(Ex. 84);




or




(Ex. 85);




or




(Ex. 86);




or




(Ex. 87);




or




(Ex. 88);




or




(Ex. 89);




or




(Ex. 90);




or




(Ex. 91);




or




(Ex. 92);




or




(Ex. 93);




or




(Ex. 94);




or




(Ex. 95);




(Ex. 96);




(Ex. 97);




(Ex. 98);




(Ex. 99);




(Ex. 101);




(Ex. 102);




(Ex. 103);




(Ex. 104);




(Ex. 105);




(Ex. 106);




(Ex. 107);




(Ex. 108);




(Ex. 109);




(Ex. 110), (Ex. 111) and (Ex. 112);




(Ex. 113);




(Ex. 114);




(Ex. 115);




(Ex. 116);




(Ex. 117);




(Ex. 118);




(Ex. 119);




(Ex. 120);




(Ex. 121);




(Ex. 121a);




(Ex. 122);




(Ex. 123);




(Ex. 124);




(Ex. 125);




(Ex. 126);




(Ex. 127);




(Ex. 128);




(Ex. 129);




(Ex. 130);




(Ex. 131);




(Ex. 132);




(Ex. 133);




(Ex. 134);




(Ex. 135);




(Ex. 136);




(Ex. 137);




(Ex. 138);




(Ex. 139);




(Ex. 140);




(Ex. 141a);




(Ex. 141b);




(Ex. 142);




(Ex. 143);




(Ex. 144);




(Ex. 145);




(Ex. 146);




(Ex. 147);




(Ex. 148);




(Ex. 149a);




(Ex. 149b);




(Ex. 150);




(Ex. 151);




(Ex. 152);




(Ex. 153);




(Ex. 154);




(Ex. 155);




(Ex. 156);




(Ex. 157);




(Ex. 158);




(Ex. 159);




(Ex. 160);




(Ex. 161);




(Ex. 162);




(Ex. 163);




(Ex. 164);




(Ex. 165);




(Ex. 166);




(Ex. 167);




(Ex. 168);




(Ex. 169);




(Ex. 170);




(Ex. 171);




(Ex. 172);




(Ex. 173);




(Ex. 174);




(Ex. 175);




(Ex. 176);




(Ex. 177);




(Ex. 178);




(Ex. 179);




(Ex. 180);




(Ex. 181);




(Ex. 182);




(Ex. 183);




(Ex. 184);




(Ex. 185);




(Ex. 186);




(Ex. 187);




(Ex. 188);




(Ex. 189);




(Ex. 190);




(Ex. 191);




(Ex. 192);




(Ex. 193);




(Ex. 194);




(Ex. 195);




(Ex. 196);




(Ex. 197);




(Ex. 198);




(Ex. 199);




(Ex. 200);




(Ex. 201);




(Ex. 202);




(Ex. 203);




(Ex. 204);




(Ex. 205);




(Ex. 206);




(Ex. 207);




(Ex. 208);




(Ex. 209);




(Ex. 210);




(Ex. 211);




(Ex. 212);




(Ex. 213);




(Ex. 214);




(Ex. 215);




(Ex. 216);




(Ex. 217);




(Ex. 218);




(Ex. 219);




(Ex. 220);




(Ex. 221);




(Ex. 222);




(Ex. 223);




(Ex. 224);




(Ex. 225) and (Ex. 226);




(Ex. 227);




(Ex. 228);




(Ex. 229);




(Ex. 230);




(Ex. 231);




(Ex. 232);




(Ex. 233);




(Ex. 234);




(Ex. 235);




(Ex. 236) and (Ex. 237);




(Ex. 238);




(Ex. 239);




(Ex. 240);




(Ex. 241);




(Ex. 242);




(Ex. 243);




(Ex. 244);




(Ex. 245);




(Ex. 246);




(Ex. 247);




(Ex. 248);




(Ex. 249);




(Ex. 250);




(Ex. 251);




(Ex. 252);




(Ex. 253);




(Ex. 254);




(Ex. 255);




(Ex. 256);




(Ex. 257);




(Ex. 258);




(Ex. 259);




(Ex. 260);




(Ex. 261);




(Ex. 262);




(Ex. 263);




(Ex. 264);




(Ex. 265);




(Ex. 266);




(Ex. 267);




(Ex. 268);




(Ex. 269);




(Ex. 270);




(Ex. 271);




(Ex. 272);




(Ex. 273);




(Ex. 274);




(Ex. 275);




(Ex. 276);




(Ex. 277);




(Ex. 278);




(Ex. 279);




(Ex. 280);




(Ex. 281);




(Ex. 282);




(Ex. 283);




(Ex. 284);




(Ex. 285);




(Ex. 286);




(Ex. 287);




(Ex. 288);




(Ex. 289);




(Ex. 290);




(Ex. 291);




(Ex. 292);




(Ex. 293);




(Ex. 294);




(Ex. 295);




(Ex. 296);




(Ex. 297);




(Ex. 298);




(Ex. 299);




(Ex. 300);




(Ex. 301);




(Ex. 302);




(Ex. 303);




(Ex. 304);




(Ex. 305);




(Ex. 306);




(Ex. 307);




(Ex. 308);




(Ex. 309);




(Ex. 310);




(Ex. 311);




(Ex. 312);




(Ex. 313);




(Ex. 314);




(Ex. 315);




(Ex. 316);




(Ex. 317);




(Ex. 318);




(Ex. 319);




(Ex. 320);




(Ex. 321);




(Ex. 322);




(Ex. 323);




(Ex. 324);




(Ex. 325);




(Ex. 326);




(Ex. 327);




(Ex. 328);




(Ex. 329);




(Ex. 330);




(Ex. 331);




(Ex. 332);




(Ex. 333);




(Ex. 334);




(Ex. 335);




(Ex. 336);




(Ex. 337);




(Ex. 338);




(Ex. 339);




(Ex. 340);




(Ex. 341);




(Ex. 342);




(Ex. 343);




(Ex. 344);




(Ex. 345);




(Ex. 346);




(Ex. 347);




(Ex. 348);




(Ex. 349);




(Ex. 350);




(Ex. 351);




(Ex. 352);




(Ex. 353);




(Ex. 354);




(Ex. 355);




(Ex. 356);




(Ex. 357);




(Ex. 358);




(Ex. 359);




(Ex. 360);




(Ex. 361);




(Ex. 362);




(Ex. 363);




(Ex. 364);




(Ex. 365);




(Ex. 366);




(Ex. 367);




(Ex. 368);



(Ex. 369);




(Ex. 370); or




(Ex. 371).

14. The compound of claim 13, or a pharmaceutically acceptable salt thereof, wherein the compound is




.

15. The compound of claim 13, or a pharmaceutically acceptable salt thereof, wherein the compound is




.

16. The compound of claim 13, or a pharmaceutically acceptable salt thereof, wherein the compound is




.

17. The compound of claim 13, or a pharmaceutically acceptable salt thereof, wherein the compound is




.

18. The compound of claim 13, or a pharmaceutically acceptable salt thereof, wherein the compound is




.

19. The compound of claim 13, or a pharmaceutically acceptable salt thereof, wherein the compound is




.


20. The compound of claim 13, or a pharmaceutically acceptable salt thereof, wherein the compound is




21. The compound of claim 13, or a pharmaceutically acceptable salt thereof, wherein the compound is



22. The compound of claim 13, or a pharmaceutically acceptable salt thereof, wherein the compound is



23. The compound of claim 13, or a pharmaceutically acceptable salt thereof, wherein the compound is



24. A pharmaceutical composition, comprising the compound of any one of claims 1-23 or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, and at least one of pharmaceutically acceptable excipients.

25. Use of the compound of any one of claims 1-23, or a pharmaceutically acceptable salt thereof, or a

stereoisomer thereof in the manufacture of a medicament for treating dysregulated apoptotic diseases.

26. The use of claim 25, wherein the dysregulated apoptotic disease is a neurodegenerative condition, proliferative diseases, or pro-thrombotic conditions.